Neurology · AntiemeticSafety Signalregulatorynear-term

Orbit Pharma recalls Cyclizine Lactate due to GMP deficiencies

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Orbit Pharma Limited1 signalView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:33:23 PM

Assessment confidence: 54% · The main uncertainty is limited high-relevance corpus coverage for this sub-indication.

Executive Thesis

The recall of Cyclizine Lactate due to GMP deficiencies poses significant risks to supply chains and market availability in the antiemetic sector. This situation necessitates close monitoring of regulatory responses and competitor actions to safeguard market positioning. Regulatory context from MHRA (Class 3 Medicines Recall: Orbit Pharma Limited, Cyclizine Lactate 50 mg/ml Solution for injection, EL(26)A/29) supports the near-term read. Assessment grounded in 16 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on market share and consider strategies to mitigate supply disruptions. The strongest clinical anchor is A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antiemetic, 3 regulatory and 4 competitive items passed relevance filtering for Orbit Pharma Limited.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This recall may impact supply and availability of Cyclizine Lactate, potentially affecting competitors in the antiemetic market.

Regulatory Outlook

Regulatory risk is concentrated around Class 3 Medicines Recall: Orbit Pharma Limited, Cyclizine Lactate 50 mg/ml Solution for injection, EL(26)A/29 (MHRA). Entity match (orbit pharma limited). Relevant agencies in corpus: MHRA, FDA. The GMP deficiencies could lead to increased scrutiny from health authorities, impacting future approvals and compliance for Orbit Pharma.

Key Risks

Elevated high regulatory exposure for Orbit Pharma Limited could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

The recall may lead to temporary supply shortages, affecting market share for Orbit Pharma and potentially benefiting competitors if they can capitalize on the disruption.
Upside for Orbit Pharma Limited may improve if Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Orbit Pharma Limited may improve if A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this recall on market share and consider strategies to mitigate supply disruptions.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any regulatory actions taken by health authorities.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Class 3 Medicines Recall: Orbit Pharma Limited, Cyclizine Lactate 50 mg/ml Solution for injection, EL(26)A/29
MHRAhigh relevance
Entity match (orbit pharma limited)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and Safety of PN+HA (NEWEST) for the Improvement of Skin Hydration
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Medline Industries Expands Catheter Recall Due to Infection Risk
Humanexa Signalsmedium relevance
Moderate corpus alignment

Safety and immunogenicity of a booster dose of COVAC-2, Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre tria
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Orbit Pharma Limited

Commercial impact

medium

The recall may lead to temporary supply shortages, affecting market share for Orbit Pharma and potentially benefiting competitors if they can capitalize on the disruption.

Regulatory impact

high

The GMP deficiencies could lead to increased scrutiny from health authorities, impacting future approvals and compliance for Orbit Pharma.

What to watch

Monitor for updates on the recall process and any regulatory actions taken by health authorities.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.